2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Conditions
Prostatic Neoplasms
43
Prostatic Neoplasms, Castration-Resistant
6
Neoplasm Metastasis
5
Metastatic Castration-resistant Prostate Cancer
4
Breast Neoplasms
4
Prostate Carcinoma Metastatic to the Bone
2
Neoplasms
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Hormone Refractory Prostate Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Prostate Adenocarcinoma
1
Pain
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Denosumab
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Quality of Life
2
Proton Therapy
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Neoplasms
×
radium Ra 223 dichloride
×
Clear all
NCT04681144
2023-10-26
QOLRAD
Bayer
Completed
103 enrolled